Pharmaceuticals

Respiratory Disease Vaccine Market Outlook Highlighting Key Drivers And Market Evolution

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Respiratory Disease Vaccine Market From 2026 To 2030?

The respiratory disease vaccine market has recently experienced a slight expansion in its size. Looking ahead, this market is projected to expand from $70.03 billion in 2025 to $71.36 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 1.9%. The expansion observed in the historic period stemmed from factors such as the high prevalence of respiratory infections, the limited availability of effective vaccines, governmental immunization initiatives, advancements in monoclonal antibody research, and an increasing awareness about respiratory health.

The respiratory disease vaccine market is projected to experience consistent expansion over the upcoming years. By 2030, its valuation is anticipated to reach $81 billion, exhibiting a compound annual growth rate (CAGR) of 3.2%. This forecasted increase is driven by several factors, including a rising need for universal vaccines, breakthroughs in mRNA and viral vector vaccine technologies, the broadening of cold-chain infrastructure, the rise of public-private collaborations for vaccine delivery, and an emphasis on readiness for pandemics and swift action. Key developments expected during this period involve the creation of advanced respiratory vaccines, a greater emphasis on vaccinating children and the elderly, the scaling up of immunization initiatives in developing regions, the emergence of combination vaccines for defense against multiple pathogens, and the implementation of swift vaccine creation and distribution systems.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

Which Important Drivers Are Guiding The Respiratory Disease Vaccine Market Growth?

An increase in tuberculosis (TB) cases is anticipated to drive the expansion of the respiratory disease vaccine market in the future. Caused by Mycobacterium tuberculosis, TB is a contagious respiratory condition that primarily impacts the lungs and poses a serious worldwide health risk. This surge in TB infections stems from elements like inadequate healthcare infrastructure, delayed diagnoses, and more widespread transmission patterns, collectively increasing the burden of the disease. Respiratory disease vaccines are vital for lessening TB-associated dangers by lowering infection rates, curbing its spread, and backing international prevention efforts. For example, as reported in March 2024 by the Centers for Disease Control and Prevention, a US-based government agency, tuberculosis cases climbed from 8,320 in 2022 to 9,615 in 2023, showing an increase of 1,295 cases. Consequently, the growing occurrence of tuberculosis is fueling the expansion of the respiratory disease vaccine market.

What Are The Main Segments Within The Respiratory Disease Vaccine Market Segment Structure?

The respiratory disease vaccine market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine

2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections

3) By Age: Infant, Adolescent, Adult

4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine

2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine

3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine

Which Trends Are Shaping Growth In The Respiratory Disease Vaccine Market?

Leading enterprises within the respiratory disease vaccine market are prioritizing the development of novel products to boost effectiveness and offer enhanced solutions for the prevention and treatment of respiratory disease infections. An illustration of this trend is the Food and Drug Administration (FDA) approval granted in May 2023 to Pfizer Inc., a US-based pharmaceutical firm, for ABRYSVO (Respiratory Syncytial Virus Vaccine). This bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine is intended to prevent lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older. ABRYSVO is characterized as an unadjuvanted vaccine, formulated with a pair of preF proteins specifically designed to optimize immunity against RSV A and B varieties, and its safety and productivity have been established through clinical trials.

Who Are The Companies Participating In The Respiratory Disease Vaccine Market?

Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc, CureVac N.V., Incepta Vaccine Ltd, Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

Get The Full Respiratory Disease Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Which Region Is The Leading Market For The Respiratory Disease Vaccine Market?

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Respiratory Disease Vaccine Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Browse Through More Reports Similar to the Global Respiratory Disease Vaccine Market 2026, By The Business Research Company

Respiratory Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Influenza Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795